Literature DB >> 24399004

Clinical aggression of prolactinomas: correlations with invasion and recurrence.

Mihaela N Popescu1, Elena Ionescu, L C Iovănescu, B V Cotoi, A I Popescu, Anca Elena Gănescu, Adina Glodeanu, Cristiana Geormăneanu, Andreiana Moraru, Anca Pătraşcu.   

Abstract

Some hypophyseal adenomas are discrete, well-marked lesions, which can be curatively removed by surgical resection, while others seem aggressive, invasive, recidive-prone, most often progressing in spite of any pharmacological, surgical or radiotherapeutical interventions. There is also a great variability within the incidence of aggression and invasion among the various types of hypophyseal immunotypes. Despite their well-differentiated nature and their "benign" constitution, an important number of hypophyseal tumors will be surely invasive within the sclerous, osseous and neural structures. Because the aggressive behavior of invasive adenomas is generally resolved by surgical treatment, this aspect of their biology does not perfectly reflect within their histopathological aspect. In fact, the invasive tumors with local extreme aggression are most often deceiving due to their relatively harmless histopathological aspect. The usual morphological signs of tumor aggression, namely pleomorphism, nuclear atypia, hemorrhage, high cellular and mitotic activity, poorly correlate with the invasive potential of pituitary tumors, with their proliferation capacity, their tendency of post-surgical recurrence or with their global biological behavior.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24399004

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  5 in total

Review 1.  Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.

Authors:  Jintao Hu; Xin Zheng; Weihua Zhang; Hui Yang
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

2.  Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.

Authors:  Youtu Wu; Jiwei Bai; Zhenye Li; Fei Wang; Lei Cao; Chunhui Liu; Shengyuan Yu; Guoqiang Yu; Yazhuo Zhang
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

3.  Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Authors:  Sema Ciftci Dogansen; Ozlem Soyluk Selcukbiricik; Seher Tanrikulu; Sema Yarman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

4.  Refractory pituitary adenoma: a novel classification for pituitary tumors.

Authors:  Congxin Dai; Ming Feng; Xiaohai Liu; Sihai Ma; Bowen Sun; Xinjie Bao; Yong Yao; Kan Deng; Yu Wang; Bing Xing; Wei Lian; Dingrong Zhong; Wenbin Ma; Renzhi Wang
Journal:  Oncotarget       Date:  2016-12-13

5.  Whole-exome sequencing identifies variants in invasive pituitary adenomas.

Authors:  Xiaolei Lan; Hua Gao; Fei Wang; Jie Feng; Jiwei Bai; Peng Zhao; Lei Cao; Songbai Gui; Lei Gong; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.